RU2217132C2 - Preparation for treating serous mastitis in cows and method for its application - Google Patents

Abstract

FIELD: veterinary science. SUBSTANCE: the suggested innovation deals with medicinal preparations for treating serous mastitis in cows including organic medicinal preparations and solvents. Moreover, as organic medicinal preparations one should apply 1.4-di-N-oxide of 2.3-bis-(oxymethyl)quinoxaline, methyl ether of paraoxybenzoic acid and dimethylsulfoxide, and as polymer-prolongator - propandiol 1.2, moreover, these substances are taken at the following ratio, (%): 1.4-di-N- oxide of 2.3-bis- (oxymethyl)quinoxaline 1.0-1.5, dimethylsulfoxide 5.0-6.5, propandiol 1.2 48.5-50.0, methyl ether of paraoxybenzoic acid 0.5-1.0, distilled water - the rest. The suggested method for treating serous mastitis in cows includes intercysternal introduction of antimastitis preparation and deals with introduction of medicinal preparation into affected portion of cow's udder at the dosage of 5-10 ml once daily for 3 d. Both preparation and method of its application enable to increase economical efficiency of therapy due to decreased labor expenses and financial expenses to purchase medicinal products by 3.5 times, shortened terms of therapy by 1.5 times and increased therapeutic efficiency by 2.7 times. EFFECT: higher efficiency of therapy. 3 cl, 2 ex

Description

 The invention relates to veterinary medicine, in particular to medicines used to treat serous mastitis in cows, and methods of using these drugs.

 A known drug and method for the treatment of serous mastitis in cows with masticide (Veterinary law. - M .: Kolos, 1981. - S. 327-328). The drug contains penicillin, streptomycin, sulfadimezin and norsulfazole, suspended in vegetable oil. The drug is administered for two to three days twice a day every 12 hours.

 A known method of treatment with mastisan E (Obstetrics, gynecology and biotechnology of reproduction. - M .: Kolos, 2000. - P.327). The drug contains erythromycin base, sulfadimezin and an oil base. 5-10 ml are injected into the nipple udder twice a day for 2-3 days.

 The disadvantages of these drugs and methods of their use include a relatively low therapeutic and prophylactic effect, the possibility of developing antibiotic resistance, long waiting times for the use of milk for food purposes (4-6 days after the last injection of the drug), significant labor and material costs.

 Closest to the proposed and adopted for the prototype is dioxidine 1% solution and its use. The composition of the drug includes 1,4-di-N-oxide 2,3 bis- (oxymethyl) quinoxaline, a preservative and water for injection. The drug is used to treat clinical and subclinical forms of mastitis and for prophylactic sanitizing treatment of the udder at the beginning of the dry period. Depending on the indications, the drug is injected into the nipple of the udder in doses of 10 to 30 ml twice a day for 2-4 days.

The disadvantages of this drug and its method of use include the absence of a prolonging effect, the instability of the dosage form, which does not preclude additional manipulations before administration (heating in a water bath until the precipitate dissolves when the drug is stored below 15 ^o C), significant material and labor costs excessive trauma to animals.

 The technical problem solved by this invention is to expand the range of tools and methods for the treatment of serous mastitis in cows.

The essence of the invention lies in the fact that the preparation for the prevention and treatment of clinical forms of mastitis in cows contains 1,4-di-N-oxide 2,3-bis- (hydroxymethyl) quinoxaline, propanediol 1,2, dimethyl sulfoxide, methyl paraoxybenzoic acid, distilled water, according to the invention, these substances are contained in the following ratio of components, g / l:
1,4-di-N-oxide 2,3-bis- (oxymethyl) quinoxaline - 10.0
dimethyl sulfoxide - 50.0
propanediol 1.2 - 500.0
paraoxybenzoic acid methyl ester - 10.0
distilled water - the rest
1,4-di-N-oxide 2,3-bis- (oxymethyl) quinoxaline is a broad-spectrum antimicrobial preparation, belongs to the group of quinoxaline derivatives. It is active against vulgar protea, Pseudomonas aeruginosa, Salmonella, staphillococci, streptococci, pathogenic anaerobes and bacterial strains resistant to other chemotherapeutic drugs.

 Dimethyl sulfoxide is a surfactant that has bactericidal, anesthetic and anti-inflammatory properties. It quickly penetrates deep into the tissues through the skin, mucous membranes and cell membranes. At the same time, it carries with it the substances dissolved in it, which ensures a greater therapeutic effect.

 Propanediol 1,2 belongs to the group of polymeric materials, it is used as a solvent and prolongator of medicinal substances.

 Paraoxybenzoic acid methyl ester is used in medicine and veterinary medicine as a harmless preservative for injection and other solutions, which has a bactericidal effect already at 0.05-0.25% concentration.

 The essence of the invention also lies in the fact that in the known method of treatment, including intercisternal administration of the drug, according to the invention, the sick animals are administered the drug in the nipple of the udder in a dose of 5-10 ml three times with an interval of 24 hours.

 The drug does not cause irritation of the parenchyma of the udder, pain, is not toxic to animals. It is highly sensitive to reference strains of Pseudomonas aureginosa, Escherichia coli, Staphilococcus aureus, as well as field strains isolated from serous mastitis.

 Using the drug and the indicated method of treatment can halve the frequency of drug administration, reduce the risk of local dysbiosis and injury to animals, increase the effectiveness of treatment by 4.34 times compared with well-known methods, and reduce the recovery time by 1.5 times.

The drug is prepared in the form of a solution using a steam boiler. The technological process includes: mixing and heating the solvent to 70-80 ^o C, dissolving the components, filtering and filling into sterile vials. To obtain one liter of the drug in the usual way, the following liquid components are mixed, ml:
dimethyl sulfoxide - 50.0
propanediol 1.2 - 500.0
distilled water - 430
The prepared mixture is heated to 70-80 ^o C and the following components are dissolved in it, g:
1,4-di-N-oxide 2,3-bis- (oxymethyl) quinoxaline - 10.0
paraoxybenzoic acid methyl ester - 10.0
Preparation and bottling of the drug is carried out in compliance with the rules of asepsis and antiseptics. The finished dosage form of the drug is a light yellow transparent solution with a pH of 6.2-7.2. Available in glass bottles for running in capacity of 10 ml, 400 ml.

 The drug is used by intercisternal administration after careful secretion from the affected lobe and disinfection of the nipple. Introduced in a dose of 5-10 ml once a day for three days.

 Example 1. In the experiment there were 220 goals of black-motley breed with clinical signs of serous mastitis.

 The animals of the experimental group (140 animals) were injected with a dose of 5 ml in the nipple of the udder once a day for 3 days and oxytocin to remove accumulated exudate 5-6 minutes before milking at a dose of 40 PIECES.

 In the control group of cows (80 goals), the usual treatment regimen was used: masticide, oxytocin according to the instructions for their use.

 The effectiveness of the treatment was evaluated according to the results of a clinical examination and laboratory examination of milk (sedimentation test, reaction with a 10% mastidine solution).

 In the experimental group of 320 affected quarters of the udder, 306 lobes were healed. Recovery is noted on 3-7 days of treatment.

 In the control group of cows, out of 204 affected quarters of the udder, 46 lobes were cured for 5-10 days of treatment. The remaining sick animals were transferred to treatment with the drug.

 Material costs for a 3-day course of treatment in the experimental group were 3.5 times lower than in the control group.

 Thus, therapeutic efficacy when using the drug in a dose of 5 ml is 95.62%, while using traditional means - 22.05%.

 Example 2. In the experiment used cows black-motley breed with clinical signs of serous mastitis. In the experiment were 102 cows.

 The animals of the experimental group (62 animals) were injected with the drug at a dose of 10 ml intercisternally once a day for 3 days. The clinical signs of mastitis in the experimental group of cows became less pronounced or absent on the second day of treatment. Of 83 patients with udder lobes, 79 were cured for 3-5 days of treatment. Therapeutic efficacy was 95.30%. Complications and transition to a chronic form of the disease were not noted.

 In the control group (40 goals), the treatment adopted at the farm at the time of the studies was carried out: masticide, mastisan E.

 Of the 55 affected quarters of the udder, 43 lobes were healed for 7-11 days of treatment. The therapeutic efficacy of treatment was 78.18%.

 Thus, the therapeutic effectiveness of the drug in a dose of 5-10 ml with serous mastitis of cows is 95.30-95.62%.

 The use of this treatment method allows to increase the cost-effectiveness of treatment by reducing labor costs and material costs for the purchase of medicines by 3.5 times, reducing treatment time by 1.5 times, and increasing therapeutic efficacy by 2.7 times.

Claims (3)

1. The drug for the treatment of serous mastitis in cows, including organic medicinal substances and solvents, characterized in that as organic medicinal substances includes 1,4-di-N-oxide 2,3-bis- (hydroxymethyl) quinoxaline, methyl ether paraoxybenzoic acids, dimethyl sulfoxide and, in addition, propanediol 1,2 as an extension polymer. 2. The drug according to claim 1, characterized in that it includes components in the following ratio, g / l: 1,4-Di-N-oxide 2,3-bis- (oxymethyl) quinoxaline 10.0-15.0 Dimethyl sulfoxide 50.0-60.5 Propanediol 1.2 485.0-500.0 Para-hydroxybenzoic acid methyl ester 5.0-10.0 Distilled Water Else 3. A method of treating serous mastitis in cows, including intercisternal administration of an anti-mastitis drug, characterized in that as an anti-mastitis drug, use the drug according to claim 1 or 2, which is injected into the affected udder at a dose of 5-10 ml once a day for 3 days.